Call US - 214 - 2547 - 142

Home » Medical » Informative Data Regarding Health Analytics

Informative Data Regarding Health Analytics

Normally, competent medical experts overseeing a clinical trial in the field can observe whether a medicine is providing any benefit to patients. These physicians are completely capable of evaluating the efficacy of a medicine in a clinical study. I strongly suggest you to visit health analytics to learn more about this.
The HEOR unit is dispatched to check statistically what the doctors claim to see in the field and to look for extra, unanticipated benefits from the medicine so that Amgen can file a patent application for the unforeseen benefit. Due to the enormous number of clinical trials that have failed to show efficacy of proposed treatments, Amgen’s HEOR unit appears to be focused on salvaging any potential value or utility for an Amgen medicine that has been rejected by the medical community.
There’s a narrow line between altering data to reveal a previously unknown advantage for patients and trying to find one where none exists. Amgen’s HEOR team proposes causal linkages based on various statistical methodologies and frantically seeks data to back them up. The everyday prospect of sifting through junk in the hopes of discovering a gem may only stimulate persons with a specific mindset.
According to the HEOR personnel, data tampering continues to try to claim that pharmaceuticals rejected by medical professionals in clinical trials have some obscure, often negligible benefit to patients. The Health Economics and Outcomes Research team would like to think it’s smarter than the doctors on the ground, because they claim to be able to spot medical benefits that clinicians treating patients missed. The Amgen HEOR team research models and statistical results, in my opinion, are frequently flimsy at best and absurd at worst. At both the undergraduate and graduate levels, I teach health care economics. I have little doubt that my undergraduate students will easily dissect the assumptions, analysis, and conclusions of the Amgen HEOR studies and publications, based on how they criticise health care policy initiatives and the pharmaceutical business. Investors must wonder why Amgen pays its HEOR professionals an estimated $25 million in compensation if their work can be criticised by undergraduate students with no pharmaceutical knowledge.
The paucity of publications by Amgen’s Health Economics unit is another indicator of the unit’s poor quality. When Amgen’s researchers are able to publish their findings in peer-reviewed publications, it is a source of great satisfaction for the company. Amgen employees’ professional journal publications boost the company’s marketing initiatives, add to the company’s credibility, and make it easier to recruit top scientists. On October 2, 2007, I used the keyword “AMGEN” in the same sentence as “Health Economics” or “Outcomes Research” in the Nexis “All Full-Text Medical Journals” database. There were a total of 0 articles discovered. I then ran the same search again, this time using the “All Medline Review Article References” database, which includes journal articles from 1975 to the present. Only one study, titled “Psychological consequences associated with anemia-related fatigue in cancer patients,” was published, and it was about Amgen’s now-declining sales medicine Aranesp. I then examined the database “Healthcare Archive News,” which comprises publicity announcements and news releases on even modest scientific and medical research findings, in the hopes of discovering some actual published research by Amgen’s HEOR team. There were no articles in the database reporting any Amgen HEOR medical results, although there were a few press releases regarding David Beier and Joshua Ofman being named to lead Amgen’s HEOR group.

Post Tagged with